BIODEFENSE SCOPE, STATUTORY REQUIREMENTS AND AGENCIES
Biodefense is referred to the measures taken to restore biosecurity of a group of organism that is, or maybe, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. The growth of the market is attributed to some key driving factors such as the presence of favourable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear-armed ICBM. However, low R&D funding by the government in developing and underdeveloped economies are expected to restraint the growth of the biodefense Industry
Access Full PDF >>
The emergence of new biotechnologies provides great promise for biodefense, especially for key objectives of biosurveillance and early warning, microbial forensics, risk and threat assessment, horizon scanning in biotechnology, and medical countermeasure (MCM) development, scale-up, and delivery. Understanding and leveraging the newly developed capabilities afforded by emerging biotechnologies require knowledge about cutting-edge research and its real or proposed application(s), the process through which biotechnologies advance, and the educational and research infrastructure that promotes multi-disciplinary science. Innovation in research and technology development is driven by sector-specific needs and the convergence of the physical, chemical, material, computer, engineering, and/or life sciences. Biotechnologies developed for other sectors could be applied to biodefense, especially if the individuals involved are able to innovate in concept design and development. Of all biodefense objectives, biosurveillance seems to have reaped the most benefit from emerging biotechnologies, specifically the integration and analysis of diverse clinical, biological, demographic, and other relevant data. More recently, scientists have begun applying synthetic biology, genomics, and microfluidics to the development of new products and platforms for MCMs. Unlike these objectives, investments in microbial forensics have been few, limiting its ability to harness biotechnology advances for collecting and analyzing data. Looking to the future, emerging biotechnologies can provide new opportunities for enhancing biodefense by addressing capability gaps.
The biodefense Industry majorly consists of the players such as Bavarian Nordic, Alnylam Pharmaceuticals, Inc., SIGA Technologies, Emergent BioSolutions Inc., Cleveland Bio Labs, Dynavax Technologies, Elusys Therapeutics, Inc., Soligenix, Altimmune, and Pluristem Therapeutics.
Know More about Biodefense...??
ASK FOR 150 PAGES PDF OF THIS STUDY
Reference
- theinsightpartners.com
- springer.com